We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Johnson & Johnson (J&J), Merck and AstraZeneca are presenting positive phase 3 data supporting drugs for castration-resistant prostate cancer at this week’s meeting of the American Society of Clinical Oncology in San Francisco. Read More
Eli Lilly is picking up ImmunoGen’s camptothecin antibody-drug conjugate (ADC) platform in a $13 million deal that could eventually net ImmunoGen $1.7 billion. Read More
Novavax said it will submit the findings to global regulators during the first quarter of this year to support authorizations for adolescents. Read More
An RNA treatment targeting a rare genetic eye disease has posted disheartening phase 2/3 results, failing to significantly improve vision in those who received the drug. Read More
Global launches of novel active drug substances hit a record 84 last year, double the number of five years ago, IQVIA reported in its latest annual review of research and development trends. Read More
Opdivo, Bristol Myers Squibb’s checkpoint inhibitor, increased survival time in patients with inoperable advanced esophageal cancer, both alone and in combination with the company’s T-cell booster Yervoy (ipilimumab). Read More
VLA15, the only Lyme disease jab in clinical development, works by targeting the outer surface protein of Borrelia burgdorferi, the bacteria responsible for causing the disease. Read More
Johnson & Johnson (J&J) announced that it’s pulling the plug on atopic dermatitis trials for the drug bermekimab, a move that is costing the company $610 million. Read More